Seres Therapeutics (MCRB) Receives a Buy from H.C. Wainwright
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Seres Therapeutics (MCRB) with a $12 price target. This contrasts with the broader analyst consensus, which holds a Moderate Buy rating and an average price target of $17.00 for the healthcare stock.
H.C. Wainwright analyst Matthew Keller reiterated a Buy rating on Seres Therapeutics today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Keller is an analyst with an average return of -25.9% and a 15.94% success rate. Keller covers the Healthcare sector, focusing on stocks such as Galectin Therapeutics, Seres Therapeutics, and 60 Degrees Pharmaceuticals, Inc..
Currently, the analyst consensus on Seres Therapeutics is a Moderate Buy with an average price target of $17.00.